Originally developed as a selective estrogen receptor modulator (SERM), the FDA-approved breast cancer drug fulvestrant (21) was found to degrade estrogen receptor α (ERα) by causing conformational changes which expose hydrophobic side chains [53]. The gene discussed is ESR1; the disease is breast carcinoma.